EGFR and oropharynx cancer: Cetuximab, which targets EGFR, is an effective therapy for patients with HNSCC.31 When combined with radiotherapy in these patients, cetuximab has been found to improve overall survival over radiotherapy alone,31 but to be less efficacious than cisplatin for p16-positive oropharyngeal cancers.32,33 Cetuximab has been used frequently as an alternative radiosensitiser when cisplatin is contraindicated, despite a lack of direct evidence from randomised trials of its benefit over radiotherapy alone for those with cisplatin contraindications.